(Health Korea News / Soon-ho Lee) K-CAB, a new drug for the treatment of gastroesophageal reflux disease in the potassium-competitive gastric acid secretion inhibitor (P-CAB) class developed by HK INNO.N, ingredient name: tegoprazan Research results have shown that tegoprazan) is effective in treating intestinal disorders caused by non-narcotic analgesics (NSAIDs). Although it is still in the cell testing stage, the P-CAB agent has already been confirmed to be effective against NSAID-induced peptic ulcers, and HK Innoen is conducting clinical trials to prevent NSAID-induced peptic ulcers, so expansion of indications is expected in the future.
Professor Hyeonjeong Lee’s team from the Department of Internal Medicine at Seoul National University Hospital recently published an article in ‘Scientific Reports’, an international journal published by the world-renowned scientific journal Nature, titled ‘A new potassium-competitive acid for NSAID-induced enteropathy. A research paper titled ‘Effectiveness of the blocker tegoprazan’ was published.
This study was conducted to determine the therapeutic potential of tegoprazan for NSAID-related small intestine damage.
When intestinal disease caused by NSAIDs occurs, discontinuation of NSAIDs is basically recommended. However, among patients suffering from chronic diseases, it is often difficult to stop NSAIDs. If complications occur in the upper gastrointestinal tract after taking NSAIDs, they can be treated with proton pump inhibitors (PPIs), but there is still no drug that can treat damage to the lower intestines, such as the small intestine. It has been reported that using PPIs for intestinal damage caused by NSAIDs actually worsens mucosal damage.
For this reason, the unmet market demand for new prevention and treatment strategies for intestinal diseases caused by NSAIDs is growing.
‘K-Cap’ has proven to be effective in preventing ulcer recurrence in patients receiving NSAIDs or low-dose aspirin based on its faster and longer-lasting acid suppression effect than PPI, but its effect on NSAID-related small intestine damage is unclear.
Accordingly, Professor Hyunjeong Lee’s team treated human intestinal epithelial cells (HIEC-6, HT-29, and Caco-2) with indomethacin and ‘K-Cap’, one of the NSAID ingredients, and then analyzed cell viability, tight junction protein expression level, and inflammatory properties. Cytokine levels and cell death were evaluated.
As a result, ‘K-Cap’ significantly improved the inhibition of cell proliferation induced by indomethacin. In addition, it restored intestinal permeability by alleviating the inhibition of occludin and ZO-1 expression by indomethacin, and effectively suppressed inflammatory cytokines and small intestine epithelial cell death expressed by indomethacin.
The professor’s team explained, “‘K-Cap’ exerts a protective effect against damage to small intestine epithelial cells caused by NSAIDs. This effect includes increasing the expression level of tight junction proteins and suppressing inflammation and cell death.”
“Over the past 10 years, the incidence of NSAID-related lower gastrointestinal tract complications has increased significantly, but the incidence of upper gastrointestinal tract complications shows a clear decreasing trend,” he said. “‘K-Cap’ is a drug that can improve small intestinal epithelial cell damage caused by NSAIDs.” There is potential. “Large-scale research, including clinical research, is needed,” he emphasized.
‘K-Cap’, Korea’s 30th new drug, is a new drug for gastroesophageal reflux disease in the P-CAB series. It is characterized by its efficacy appearing quickly within 30 minutes after taking it, and its effectiveness and safety when taken long-term for up to 6 months.
Last year’s outpatient prescriptions amounted to KRW 158.2 billion, ranking first in the peptic ulcer medication market for four consecutive years since its launch. The total cumulative prescription performance of ‘K-Cap’ from 2019 to 2023 is 508.5 billion won.
The indications that ‘KCap’ has secured so far are ▲treatment of erosive gastroesophageal reflux disease ▲treatment of non-erosive gastroesophageal reflux disease ▲treatment of gastric ulcers ▲antibiotic combination therapy for Helicobacter pylori eradication ▲maintenance after treatment of erosive gastroesophageal reflux disease There are 5 therapies, etc.
In addition, HK Innoen is currently conducting a phase 3 clinical trial to evaluate the gastroduodenal ulcer prevention effect and safety of ‘K-Cap’ in patients who must take NSAIDs.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: www.hkn24.com
